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ABSTRACT 
Pharmaceuticals, once ingested, are commonly metabolized in the body into 
more polar and soluble forms. These compounds might not be completely removed in 
the wastewater treatment plants and consequently being discharged into the aquatic 
ecosystem. In this work, a multi-class sensitive method for the analysis of 21 
compounds, including 7 widely consumed pharmaceuticals and 14 relevant metabolites, 
has been developed based on the use of UHPLC-MS/MS in selected reaction 
monitoring (SRM) mode. The method was validated in six surface waters (SW) and six 
effluent wastewaters (EWW) at realistic concentration levels that can be found in 
waters. The optimized method was applied to the analysis of different types of water 
samples (rivers, lakes and effluent wastewater), detecting nearly all the parent 
compounds and metabolites investigated in this work. This fact illustrates that not only 
pharmaceuticals but also their metabolites are commonly present in these types of 
waters. Analytical research and monitoring programs should be directed not only 
towards parent pharmaceuticals but also towards relevant metabolites to have a realistic 
overview of the impact of pharmaceuticals in the aquatic environment. 
 
Keywords: Pharmaceuticals, metabolites, ultra-high performance liquid 
chromatography, tandem mass spectrometry, multi-class method, surface water, 
wastewater 
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1. INTRODUCTION 
In the last years, many papers dealing with the presence of pharmaceuticals in 
the aquatic environment have been reported. Most of the work performed until now has 
been focused on parent pharmaceuticals, while metabolites have been much less 
investigated. After human and/or veterinary consumption, pharmaceuticals can be 
excreted in unchanged form as the parent compound and/or as free or conjugated 
metabolites through urine and/or faeces. Metabolism occurs in two phases. The first one 
involves typically oxidation, reduction, or hydrolysis, and the second phase consists of 
transferring a polar group to the parent compound or the metabolite to render a 
conjugate (Khetan and Collins 2007; Mompelat et al. 2009). Obviously, not all 
pharmaceuticals are metabolised to the same extent. They may be classified in four 
classes according to the proportions of excreted parent compound (Jjemba 2006), i.e. 
low excretion ( 5%), moderately low (6-39%), relatively high (40-69%), and high 
excretion compounds ( 70%). Among the first group, there are some compounds 
known as pro-drugs, i.e., inactive substances that after their ingestion are converted to 
an active form in the body.  
Both parent pharmaceuticals and metabolites might not be fully eliminated 
during the treatment processes in wastewater treatment plants (WWTP) being 
discharged into the aquatic ecosystems through treated wastewaters. Research is 
commonly focused on parent compounds, and little is known about the presence of 
metabolites and on transformation products (TPs) that can be formed during water 
treatment. In fact, only a few works have reported values of pharmaceuticals 
metabolites and TPs in the aquatic environment
 
(González Alonso et al. 2010; Langford 
and Thomas 2011; Kovalova et al. 2012; López-Serna et al. 2012a). Although 
pharmaceuticals and metabolites are typically found at low concentration levels, the 
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effects derived from the exposure to a mixture of parent pharmaceuticals and their 
metabolites are still largely unknown. Moreover, some of the metabolites are still 
bioactive and may have high stability and mobility in the environment
 
(Gros et al. 
2012). Mompelat et al. (2009) have recently reported that only around 30 
pharmaceutical by-products (including metabolites and transformation products) have 
been included in environmental investigations.  
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) 
with triple quadrupole triple quadrupole (QqQ) analyzer is nowadays the technique of 
choice for trace analysis of pharmaceuticals due to the high selectivity and sensitivity 
achieved in selected reaction monitoring (SRM) mode. LC-MS/MS has been commonly 
used for multi-class determination of pharmaceuticals compounds, normally including 
only a few metabolites in the target list of analytes
 
(Kasprzyk-Hordern et al. 2007; Batt 
et al. 2008; Tarcomnicu et al. 2011). In the last two years, this trend is being changing, 
as more metabolites are included in the analytical methods. For example, Tarcomnicu et 
al. (2011) have developed a method for the analysis of different pharmaceuticals and 
four metabolites. Recently, a method based on automated off-line solid phase extraction 
(SPE) using a triple quadruple-linear ion trap mass spectrometer (QqLIT) has allowed 
the determination of 8 metabolites
 
(Gros et al. 2012). Another LC-MS/MS method has 
been reported using QqQ for the analysis of 19 pharmaceutical metabolites and TPs
 
(López-Serna et al. 2012b). In addition, a few papers have been published on 
investigation of pharmaceutical metabolites and TPs by high-resolution mass 
spectrometry (HR MS), emphasizing the use of hybrid quadrupole time-of-flight 
(QTOF)
 
(Martínez Bueno et al. 2007; Hernández et al. 2011; Gómez-Ramos et al. 2011; 
Ferrer and Thurman 2012). LC-HR MS has been proven to be a powerful and promising 
approach to investigate these compounds in waters from reported-known 
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metabolites/TPs to unknown compounds that share common fragments with the parent 
molecule (Hernández et al. 2011; Ibáñez et al. 2012). 
Some works have reported metabolite concentrations higher than the original 
molecule
 
(López-Serna et al. 2012a; Miao and Metcalfe 2003). This also supports the 
interest of searching for metabolites to have a wider and more realistic knowledge about 
the impact of pharmaceuticals in the aquatic environment. To this aim, multi-class 
methods including pharmaceuticals and metabolites are required, but this type of 
analysis presents some difficulties, as metabolites are usually more polar than parent 
compounds. This makes problematic their simultaneous extraction and LC 
determination, as they are less retained on the SPE cartridges and on the commonly 
used reversed-phase LC columns. In addition, the low concentrations normally present 
in waters require the use of highly sensitive methods for their determination. This is 
especially important in complex environmental matrices where the presence of co-
extracted sample matrix components results in ionization suppression or enhancement 
effects. Although matrix effects can be corrected using isotope-labelled internal 
standards (ILIS)
 
(Wille et al. 2012), the availability of ILIS reference standards is rather 
limited in comparison with parent pharmaceuticals. And last but not least, it is necessary 
to ensure the confident identification of the compound detected. This issue might be 
problematic for isomeric metabolites that share common fragments with the parent 
compound, or metabolites that can generate the parent compound as an in-source 
fragments in the LC-MS instrument
 
(Ibáñez et al. 2012). Under this situation, is 
necessary to maximize precautions to ensure right identifications, as for example using 
more than two MS/MS transitions, analysing samples by HR MS techniques, and/or 
improving the chromatographic separation. 
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In a previous work
 
(Hernández et al. 2011), five pharmaceutical metabolites 
were identified in urban wastewater samples by UHPLC-QTOF MS, after detection of 
the parent pharmaceuticals and subsequent data re-evaluation in a retrospective way. 
These compounds were N-desmethyl clarithromycin, 14-hydroxy-clarithromycin, 
fenofibric acid, clopidogrel carboxylic acid and 4-hydroxy omeprazole sulfide. Analysis 
by QTOF also allowed us to discover the presence of several metabolites of the 
analgesic dipyrone in urban wastewater
 
(Ibáñez et al. 2012). Based on these previous 
findings, we decided to widen the study of pharmaceutical metabolites and to develop a 
multi-residue sensitive method based on LC-MS/MS with triple quadrupole for the 
simultaneous quantification of relevant metabolites. In addition to those compounds 
previously detected, the list of target metabolites was completed with nine more 
compounds were reported in SW and EWW (Miao and Metcalfe 2003; Kasprzyk-
Hordern et al. 2007; Tarcomnicu et al. 2011)
 
and
 
taking into account their commercial 
availability as reference standards. Moreover, parent pharmaceuticals of the metabolites 
selected were also included in the method as they might not be completely metabolized 
(Jjemba 2006; Mompelat et al. 2009). The parent compounds clofibrate, fenofibrate and 
dipyrone were not considered because they are pro-drugs (Gómez et al. 2008; Mompelat 
et al. 2009)  and therefore, they are not expected to be found in the aquatic environment. 
 The goal of this paper is to investigate the presence of 21 pharmaceuticals, 
including seven parent compounds and their main metabolites, in environmental waters. 
To this aim, rapid and sensitive analytical methodology, based on the use of LC-MS/MS 
with triple quadrupole, has been developed . Validation of the method was made in a 
notable number of water samples (six different surface water and six different effluent 
wastewater) trying to cover quite distinct sample compositions and situations that can 
appear when analyzing real samples. Analyses of environmental water samples has 
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shown that not only parent pharmaceuticals but also their metabolites are commonly 
present in the aquatic environment, suggesting that these compounds need to be 
regularly monitored in waters.  
 
EXPERIMENTAL 
2.1. Reagents and chemicals 
Reference standards of pharmaceuticals were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Reference standards of metabolites were obtained from Toronto 
Research Chemicals (Ontario, Canada), with the exception of carbamazepine 10,11-
epoxide, enalaprilat, 4-amino antipyrine and clofibric acid, which were supplied from 
Sigma-Aldrich. Their chemical structure is shown in Figure 1. 
Isotopically labelled compounds used as ILIS (omeprazole-d3, enalaprilat-d5 and 
carbamazepine 10,11-epoxide-d10) were from CDN Isotopes (Quebec, Canada). 
HPLC-grade methanol (MeOH) was purchased from Scharlab (Barcelona, 
Spain). HPLC-grade water was obtained by purifying demineralised water in a Milli-Q 
plus system from Millipore (Bedford, MA, USA).  Formic acid (HCOOH, content > 
98%), ammonium acetate (NH4Ac, reagent grade) and ammonia (NH3, solution 32%, 
reagent grade) were supplied by Scharlab (Barcelona, Spain). 
Individual stock solutions of pharmaceuticals/metabolites (around 500 mg/L) 
were prepared dissolving an accurately weighted amount in methanol. The individual 
stock solutions were mixed and diluted with methanol to give a final concentration of 
around 1 mg/L (40% MeOH, 60% HPLC-grade water, approximately). This mix 
solution was prepared weekly, based on previous information on omeprazole stability, 
and it was subsequently diluted with HPLC-grade water to obtain working mixed 
solutions of pharmaceuticals/metabolites. These solutions were used for spiking 
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Figure 1 Structures of the selected compounds.2 Formatat: VA_Figure_Caption,
Centrada
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samples in the validation study and also for preparation of calibration standards. In the 3 
last case, the standards were prepared in methanol-water (10:90, v/v) to assure the same 4 
organic content as in the sample extracts. 5 
Individual stock solutions of ILIS were also prepared in methanol. Mix working 6 
solutions at 5 μg/L (for surface water (SW) samples) or at 50 μg/L (for effluent 7 
wastewater (EWW) samples) were prepared in HPLC-grade water and used as 8 
surrogates. 9 
All standard solutions (stock, intermediate and working solutions) were stored in 10 
amber glass bottles at −20 ⁰C in a freezer.  11 
Cartridges used for SPE were Oasis HLB (200 mg), Oasis HLB (60 mg), Oasis 12 
MCX (150 mg) and Oasis MAX (150 mg), from Waters (Milford, MA, USA). 13 
 14 
2.2. Liquid chromatography 15 
UHPLC analysis were carried out using an Acquity UPLC system (Waters 16 
Corp., Milford, MA, USA), equipped with a binary solvent manager and a sample 17 
manager. Chromatographic separation was performed using an Acquity UPLC HSS T3 18 
(C18) column, 1.8 μm, 100 mm × 2.1 mm (i.d.) (Waters) at a flow rate of 0.3 mL/min. 19 
The column was kept at 40 ⁰C and the sample manager was maintained at 5⁰C. Mobile 20 
phase consisted of a water/(methanol 0.01% HCOOH) gradient. The methanol 21 
percentage was changed linearly as follows: 0 min, 10%; 12 min, 80%; 12 min, 80%; 22 
12.1 min; 10%. Analysis run time was 13 min. The sample injection volume was 100 23 
μL (full loop). 24 
 25 
2.3. Mass spectrometry  26 
Formatat: anglès (Regne Unit)
Formatat: Normal, Justificada, Sagnia:
Primera línia:  0 cm, Interlineat:  Doble
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A TQD (triple quadrupole) mass spectrometer with an orthogonal Z-spray-27 
electrospray interface (Waters Corp., Milford, MA, USA) was used. Drying gas as well 28 
as nebulising gas was nitrogen generated from pressurized air in a N2 nitrogen LC–MS 29 
(Claind, Teknokroma, Barcelona, Spain). The cone gas and the desolvation gas flows 30 
were set at 60 L/h and 1200 L/h, respectively. For operation in MS/MS mode, collision 31 
gas was Argon 99.995% (Praxair, Valencia, Spain) at 2×10
−3
 mbar in the T-Wave 32 
collision cell. Capillary voltages of −3.0 kV (negative ionization mode) and 3.5 kV 33 
(positive ionization mode) were applied. The interface temperature was set to 500 ⁰C 34 
and the source temperature to 120 ⁰C. Dwell time, inter-channel delay time, and inter-35 
scan delay time were automatically assigned by the system software (MassLynx 4.1, 36 
Manchester, UK)  using the auto-dwell feature. 37 
 38 
2.4. Recommended procedure 39 
A volume of 50 mL of water sample were spiked with the corresponding ILIS 40 
mix working solution, giving a final concentration of 0.5 μg/L (surface water) and 5 41 
μg/L (effluent wastewater) for each individual ILIS. Oasis HLB (60 mg) cartridges used 42 
for SPE were conditioned with 3 mL MeOH and 3 mL HPLC-grade water before use. 43 
Then, the samples were passed through the cartridge by gravity and, after drying under 44 
vacuum for 15 minutes, analytes were eluted with 5 mL MeOH. The extract was 45 
evaporated to dryness under a gentle nitrogen stream at 40⁰C and reconstituted with 1 46 
mL MeOH–water (10:90, v/v). Finally, 100 μL were injected into the UHPLC–MS/MS 47 
system under the conditions shown in Table 1.  48 
Quantification was made by calibration standards in solvent, using relative 49 
responses analyte/ILIS, or absolute responses, depending whether ILIS was used for 50 
correction or not.  51 
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Table 1. MS/MS optimized conditions for selected pharmaceuticals and metabolites 52 
 53 
Compound 
ESI 
Cone 
(V) 
Q Transition 
(m/z) 
C.E. 
(eV) 
q1 Transition 
(m/z) 
C.E. 
(eV) 
q2 Transition 
(m/z) 
C.E. 
(eV) 
Q/q1
a
 Q/q2
a
 
IDL 
(pg) 
Carbamazepine + 25 237.3 > 194.2 25 237.3 > 179.2 35 237.3 > 165.2 40 4.8 7.1 0.3 
Carbamazepine 10,11-epoxide  + 15 253.4 > 180.2 20 253.4 > 236.2 10 253.4 > 210.3 20 1.7 10.7 0.9 
10,11- Dihydro-10,11-dihydroxy 
carbamazepine 
10,11- Dihydro-10,11-dihydroxy 
carbamazepime carbamazepime 
+ 15 271.0 > 180.1 30 271.0 > 253.0 5 271.0 > 236.0 10 1.5 1.7 1.6 
            Clarithromycin + 40 748.3 > 158.1 30 748.3 > 83.0 50 590.3 > 158.1
b
 25 2.2 2.4 0.3 
N-Desmethyl clarithromycin + 25 735.0 > 144.2 20 735.0 > 576.8 20 737.0 > 146.2 15 7.6 168.1 0.4 
            Clopidogrel + 25 322.0 > 212.0 15 322.0 > 184.0 25 324.0 > 214.0 15 1.5 3.1 0.3 
Clopidogrel carboxylic acid + 20 308.3 > 198.2 15 308.3 > 77.0 45 310.3 > 200.2 10 1.0 4.1 0.9 
            Enalapril + 35 377.4 > 91.1 55 377.4 > 234.2 20 377.4 > 160.2 30 2.1 4.6 1.1 
Enalaprilat + 30 349.5 > 91.1 50 349.5 > 206.3 20 349.5 > 117.2 35 2.0 2.5 10.2 
            Losartan + 20 423.2 > 207.0 25 423.2 > 405.2 15 425.2 > 207.0 25 3.0 9.0 0.4 
Losartan carboxylic acid + 25 437.2 > 207.1 30 437.2 > 235.0 20 439.2 > 207.2 20 0.5 1.6 5.7 
            Omeprazole + 30 346.3 > 198.1 10 346.3 > 136.1 35 346.3 > 151.1 20 0.9 2.0 2.6 
4-Hydroxy omeprazole sulfide + 20 316.4 > 168.2 25 316.4 > 149.2 25 316.4 > 136.2 25 1.0 1.0 0.5 
5-Hydroxy omeprazole + 15 362.1 > 152.1 35 362.1 > 214.0 20 362.1 > 196.2 30 1.7 3.2 0.5 
            Sulfamethoxazole + 40 254.0 > 64.9 50 254.0 > 91.9 30 254.0 > 155.9 20 1.2 49.4 0.7 
N-Acetyl sulfamethoxazole + 30 296.0 > 134.2 20 296.0 > 198.0 20 - - 2.8 - 0.7 
            4-Acetamido antipyrine + 20 246.4 > 83.1 25 246.4 > 228.3 15 246.4 > 104.1 20 1.6 1.6 1.2 
4-Amino antipyrine + 20 204.4 > 56.1 15 204.4 > 83.1 15 204.4 > 94.1 15 5.9 5.6 1.0 
4-Formylamino antipyrine + 25 232.4 > 56.1 25 232.4 > 83.1 20 232.4 > 104.1 20 1.6 1.0 2.9 
            Clofibric acid - 20 213.3 > 127.0 15 215.2 > 129.0 10 213.3 > 85.1 10 1.1 5.3 23.2 
            Fenofibric acid + 25 319.0 > 233.0 15 319.0 > 138.9 30 319.0 > 121.0 30 1.2 2.6 1.2 
            Carbamazepine 10,11-epoxide-d10 + 20 263.1 > 190.0 20 - - - - - - - 
Enalaprilat-d5 + 25 354.1 > 96.1 50 - - - - - - - 
Omeprazole-d3 + 30 349.3 > 198.1 10 - - - - - - - 
 54 
Abbreviations: ES (electrospray ionization), Q (quantification), q (confirmation), C.E. (collision energy), IDL (instrumental detection limit) 55 
a
Average value for seven standards, from 0.25 to 25 g/L. 56 
b
In this case an in-source fragment was used as precursor ion and the cone voltage was 55 V. 57 
In bold the parent pharmaceuticals, in italics the metabolites and with regular format, the ILIS used. 58
Formatat: Sagnia: Esquerra:  0 cm
Formatat: Superior:  2,25 cm, Inferior:
 2 cm
Taula formatada
Formatat: espanyol (Espanya - alfab.
tradicional)
 12 
 59 
2.5. Validation study 60 
Method accuracy (expressed as percentage recovery) and precision (expressed as 61 
repeatability in terms of relative standard deviation (RSD)) were estimated by means of 62 
recovery experiments in 12 different samples spiked at various concentrations (0.02 63 
g/L in SW; 0.1 and 0.4 g/L in EWW). SW samples used for validation were collected 64 
in different sites of the Mediterranean Spanish area of Valencia (Mijares and Jucar 65 
rivers, Sitjar and Mª Cristina reservoirs, Clot de Burriana lake and Albufera de 66 
Valencia). EWW samples were collected from different WWTPs of the same area. For 67 
each individual sample, recovery experiments were performed by triplicate, giving a 68 
total of 18 data for SW and 18 for EWW at each spiked concentration. 69 
For each sample under study, the limit of quantification (LOQ) was estimated 70 
for a signal-to-noise ratio (S/N) of 10 from the sample chromatograms at the lowest 71 
validation level tested, using the quantification transition.  In this way, average LOQ 72 
and the interval (both in ng/L) were estimated for both SW and EWW samples. True 73 
blank samples were not found for several analytes, as they were already present in the 74 
samples tested. In these cases, LOQs were estimated from the analyte levels quantified 75 
in the non-spiked samples. The instrumental detection limit (IDL) was estimated for 76 
S/N = 3 from the chromatogram of the standard at the lowest concentration level tested 77 
in the calibration curve. 78 
Linearity of the method was studied by analyzing standard solutions in triplicate 79 
at seven concentrations in the range from 0.25 to 25 g/L (equivalent to 0.005-0.5 g/L 80 
in the water sample). Satisfactory linearity using least squares regression was assumed 81 
when the correlation coefficient (r) was higher than 0.99 and residuals lower than 30% 82 
Formatat: Sagnia: Primera línia:  0 cm
Formatat: Esquerra
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without significant trend, based on absolute responses, except for those compounds that 83 
were quantified with ILIS (relative responses). 84 
 85 
 86 
2.6. Application to environmental samples 87 
The method was applied to twenty-four samples (12 SW and 12 EWW samples). 88 
Regarding surface water, they were collected in selected sites of the Spanish 89 
Mediterranean area (Castellón and Valencia provinces), corresponding to 4 rivers, 2 90 
reservoirs and 6 lakes. In the case of wastewater, samples consisted on 24-h composite 91 
urban wastewater samples and were collected along time from 4 different WWTPs 92 
located in the Castellon area. All samples were stored in the dark at <−18 ◦C in 93 
polyethylene high-density bottles until analysis. Immediately before analysis, samples 94 
were thawed at room temperature. 95 
 96 
3. RESULTS AND DISCUSSION 97 
3.1. MS and MS/MS optimization  98 
Full-scan and MS/MS mass spectra were obtained from infusion of 1 mg/L 99 
individual standard solutions in methanol/water (50:50, v/v) at a flow rate of 10 L/min. 100 
All compounds were determined in positive ionisation mode, with the exception of 101 
clofibric acid. Although this analyte might be analyzed in both positive and negative 102 
modes, the latter was preferred because of the better sensitivity reached under this 103 
mode. Mass spectrometry parameters, precursor and product ions selected, IDLs and ion 104 
ratios (Q/q) used for confirmation are shown in Table 1. 105 
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All compounds showed an abundant [M+H]
+
 ion (for clofibric acid. [M-H]
-
) 106 
which was selected as precursor ion. For clopidogrel, clopidogrel carboxylic acid, 107 
losartan, losartan carboxylic acid and clofibric acid, the presence of one chlorine atom 108 
in their structure allowed the use of two different precursor ions (corresponding to 
35
Cl 109 
and 
37
Cl isotopes). 110 
For clarithromycin, an additional sensitive transition was obtained selecting an 111 
in-source fragment by increasing the cone voltage. The fragmentation of this in-source 112 
fragment ion produced a highly abundant product ion, making possible the acquisition 113 
of other sensitive transition (see q2 transition for the mentioned pharmaceutical in Table 114 
1). 115 
Three SRM transitions were selected for each compound to assure the reliable 116 
confirmation of the compounds detected in water samples. The most sensitive transition 117 
was used for quantification (Q) whereas the other two were used for confirmation (q1 118 
and q2). For N-acetyl sulfamethoxazole only one confirmation transition could be 119 
monitored due to its poor fragmentation.   120 
The method was divided in 24 overlapping retention time windows (one window 121 
per compound) and MRM data acquisition rates (dwell time, inter-channel delay time, 122 
inter-scan delay times) were automatically optimized. 123 
 124 
3.2. Chromatographic optimization 125 
In order to optimize chromatographic separation, both methanol and acetonitrile 126 
solvents as well as different HCOOH and NH4Ac contents were evaluated. Acetonitrile 127 
was discarded because sensitivity decreased for most compounds in comparison with 128 
MeOH. Regarding the modifiers, the use of NH4Ac led to worse sensitivity compared 129 
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with HCOOH. Besides, the addition of HCOOH favoured the retention of acidic 130 
compounds in the LC column, such as losartan carboxylic acid or clofibric acid. Thus, 131 
for losartan, the retention time shifted from 6.28 min (NH4Ac 5 mM) to 9.19 min 132 
(HCOOH, 0.01%). This behaviour was similar for clofibric acid (from 6.62 min to 9.28 133 
min). On the contrary, for a few analytes the chromatographic run time decreased when 134 
HCOOH was added, especially for clarithromycin, which eluted the latest. However, 135 
enalapril and its metabolite presented a worse peak shape when acid was present in the 136 
mobile phase. This situation is quite usual when compounds with very different 137 
physico-chemical characteristics are simultaneously analysed, and obviously a 138 
compromise has to be reached. Finally, the addition of HCOOH was tested in both 139 
organic and aqueous solvents, obtaining best results (in terms of sensitivity) when this 140 
modifier was added only to the MeOH. 141 
Once the mobile phase was selected (water/(MeOH 0.01% HCOOH)), two 142 
UHPLC C18 columns were compared (HSS T3 and BEH, both 10 cm). The results were 143 
similar showing that both columns are suitable for the retention of a broad group of 144 
compounds with different polarity. Finally, HSS T3 column was selected because the 145 
analytes were more retained and peak shape was better (narrower peaks) for a few 146 
compounds such as losartan carboxylic acid and enalaprilat. 147 
After testing several injection volumes (20, 50 and 100 µL), the optimum was 148 
found to be 100 µL due to the increased sensitivity without affecting the peak shape. 149 
Column temperature was maintained at 50 ºC to improve peak shape of enalapril
 
150 
(Gracia-Lor et al. 2010).  151 
 152 
3.3 Solid phase extraction optimization 153 
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Metabolites are usually more polar than parent compounds, making their 154 
simultaneous extraction more problematic. Therefore, the optimization of the SPE step 155 
is especially important in this case. In this work, the extraction efficiency of three 156 
cartridges was checked (Oasis HLB (200 mg), Oasis MCX (150 mg) and Oasis MAX 157 
(150 mg)), using HPLC-grade water spiked with the analytes. Oasis HLB can be used 158 
for a wide range of target compounds with quite distinct polarities, while MCX is 159 
suitable for compounds with basic groups and MAX for acidic compounds. Oasis HLB 160 
was tested at neutral pH, while MCX required acidification of the water sample (pH 2) 161 
to ensure protonation of basic compounds, and MAX required working at basic medium 162 
(pH 11) in order to fully deprotonate acidic compounds. After loading the samples, the 163 
cartridges were dried under vacuum for 15 min. The elution was carried out with 8 mL 164 
MeOH (HLB), with 4 mL MeOH followed by 4 mL MeOH 5% NH4OH (MCX), or 165 
with 4 mL MeOH followed by 4 mL MeOH 5% HCOOH (MAX). 166 
Our results showed that recoveries for N-desmethyl clarithromycin and 167 
carbamazepine 10,11-epoxide were lower using MCX (around 30%). The first one is 168 
expected to be efficiently retained on MCX cartridge due to the protonation of the 169 
amino group. A possible explanation for these unexpected results might be that the 170 
elution with 4 mL MeOH 5% NH4OH was not enough to break its strong retention in 171 
the cartridge, yielding to poor recoveries. On the contrary, the acidification of the water 172 
sample would generate the diol group through the epoxide ring opening of 173 
carbamazepine 10,11-epoxide, being partially converted into 10,11-dihydro-10,11-174 
dihydroxy carbamazepine, and leading to low SPE recoveries. 175 
In general, recoveries with HLB and MAX were quite similar, although the first 176 
one showed more reproducible figures for all the compounds (data not shown). 177 
Therefore, HLB cartridges were selected for subsequent experiments. Then, a 178 
 17 
comparison between Oasis HLB containing 60 mg and 200 mg was carried out, eluting 179 
with 5 and 8 mL MeOH, respectively. As similar results were obtained for all 180 
compounds, Oasis HLB 60 mg was selected to economize the amount of stationary 181 
phase. Finally, this cartridge was tested adjusting the pH of the sample loaded at three  182 
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Figure 2 Recoveries obtained for 19 selected compounds after SPE with Oasis HLB (60 mg) at different sample pH values. Clopidogrel and 184 
losartan recoveries are not shown because their standards were not available at the laboratory when this test was carried out. 185 
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values (pH 3, 7 and 9) (see Figure 2). As a compromise, neutral pH was selected for 186 
sample extraction, as nearly all compounds showed satisfactory recoveries (between 70 187 
and 120%), with the exception of 4-amino antipyrine (4-AA) and enalaprilat (recoveries 188 
around 40%).  189 
 190 
3.4 Method validation 191 
The linearity of the method was satisfactory between 0.25 - 25 g/L for all 192 
compounds. These values corresponded to 0.005-0.5 g/L in the water sample, taking 193 
into account the 50-fold pre-concentration factor applied along the sample procedure. 194 
For validation purposes, each of the 12 water samples selected (6 SW and 6 EWW) 195 
were spiked at different concentration levels (0.02 g/L in SW; 0.1 and 0.4g/L in 196 
EWW). Experiments were performed by triplicate for each spiked sample. Recoveries 197 
were determined by comparing the concentration obtained after applying the 198 
recommended procedure with the nominal concentration of the spiked samples, 199 
performing quantification by standards calibration in solvent. Non- spiked samples, 200 
containing only the ILIS mix, were also processed to subtract the concentration of the 201 
target analyte when it was present in the sample used in the recovery experiments.  202 
The method was tested at 0.02 g/L in the surface water samples (recoveries 203 
shown in Table 2). A few compounds could not be properly validated in one of the 204 
samples tested (Jucar river) due to the high analyte concentration found in the “non-205 
spiked” sample. Enalaprilat and clofibric acid could not be validated in some samples 206 
due to the low sensitivity observed for these compounds, which would have required 207 
higher spiking levels to be validated. With very rare exceptions, data were satisfactory 208 
(between 70% and 120%) for most of the compounds. In a few cases, recoveries varied 209 
significantly from one sample to another. This was the case of clarithromycin  210 
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Table 2. Method validation for surface water. Recovery (%) and relative standard deviation (RSD, %) for six different SW samples spiked at 0.02 211 
g/L. Each sample was analyzed in triplicate. 212 
 213 
Compound 
 Recovery (%) Average 
recovery 
(%) 
Average 
LOQ 
(ng/L) 
LOQ range 
(ng/L) tR(min) Sitjar 
reservoir 
M
a 
Cristina 
reservoir 
Clot lake Jucar river Mijares 
river 
Albufera 
lake 
Carbamazepine 8.32 72 59 85 90 99 56 77 (22) 0.6 0.3 – 0.7 
Carbamazepine 10,11-epoxide 6.94 106 99 67 94 110 61 89 (23) 
2.7 1.7 – 3.7 
Carbamazepine 10,11-epoxide* 39 55 70 90 57 63 62 (27) 
10,11- Dihydro-10,11-
dihydroxy carbamazepine 
6.57 177 217 177 a 140 127 168 (21) 2.2 1.4 – 3.8 
            Clarithromycin 9.20 107 100 52 53 64 66 74 (32) 1.9 1.3 – 2.6 
N-Desmethyl clarithromycin 9.24 101 88 69 69 73 53 75 (22) 2.5 0.6 – 4.4 
            Clopidogrel 11.23 50 40 52 39 38 36 43 (16) 0.4 0.2 – 0.7 
Clopidogrel carboxylic acid 6.25 82 101 101 50 121 94 91 (26) 1.1 0.5 – 2.0 
            Enalapril 7.45 80 111 91 103 105 155 107 (24) 22.8 8.9 – 47.6 
Enalaprilat 4.93 b b b b b b b - - 
Enalaprilat* b b b b b b b 
            Losartan 9.19 105 109 104 101 128 131 113 (12) 1.3 0.6- 2.8 
Losartan carboxylic acid 9.50 120 130 121 108 162 153 132 (16) 5.4 1.7 – 7.5 
            Omeprazole 7.99 161 237 167 207 176 345 215 (32) 
2.4 2.2 – 2.8 
Omeprazole* 102 68 70 87 103 93 87 (18) 
4-Hydroxy omeprazole sulfide 6.83 88 102 84 84 80 75 85 (11) 2.3 1.9 – 2.7 
5-Hydroxy omeprazole 6.82 123 145 149 150 131 156 142 (9) 3.0 2.2 – 3.3 
            Sulfamethoxazole 4.79 98 77 112 106 112 70 96 (19) 7.7 4.0 – 24.8 
N-Acetyl sulfamethoxazole 5.90 120 95 128 97 143 95 113 (18) 3.9 2.0 – 7.1 
            4-Acetamido antipyrine 4.09 87 116 114 a 122 66 101 (23) 3.0 0.9 – 6.6 
4-Amino antipyrine 4.42 44 51 76 a 33 52 51 (31) 1.6 0.6 – 3.5 
4-Formylamino antipyrine 3.99 95 136 111 a 142 103 117 (18) 2.7 1.3 – 5.5 
            Clofibric acid 9.28 108 90 83 62 b b 86 (22) 24.5 17.1 – 30.6 
            Fenofibric acid 10.86 80 61 83 a 67 101 78 (20) 1.9 1.2 – 2.5 
a: Not estimated due to the high analyte levels found in the “blank” sample; b: Not estimated due to the poor sensitivity. 214 
* Recoveries calculated using their own ILIS 215 
In bold the parent pharmaceuticals and with regular format, the metabolites. 216 
Formatat: anglès (Regne Unit)
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(individual recoveries between 52 - 107%). This variation might be explained by the distinct 217 
matrix effects that particularly affected to this compound and that varied notably from one water 218 
sample to another.  219 
Clopidogrel and 4-amino antipyrine presented low recoveries (around 45%) in all 220 
samples. In order to know whether poor recoveries were due to matrix effects or to poor 221 
extraction in the SPE cartridge, for each individual SW sample a extract obtained after SPE was 222 
spiked and the analyte responses compared with standards in solvent at the same concentration 223 
(data not shown). Our results showed that low clopidogrel recoveries were due to matrix effects 224 
(signal suppression). On the contrary, no relevant matrix effects were observed for 4-amino 225 
antipyrine; consequently, its low recoveries were attributed to losses during the SPE process. On 226 
the other hand, four compounds showed recoveries above 120% (losartan carboxylic acid; 10,11-227 
dihydro-10,11-dihydroxy carbamazepine; omeprazole; 5-hydroxy omeprazole) due to matrix 228 
signal enhancement. In the case of omeprazole, matrix effects could be corrected by using its 229 
own ILIS, obtaining satisfactory recoveries in all SW samples.  230 
In total, three ILIS were used in this work and tested for matrix effects correction. In 231 
addition to the above mentioned omeprazole, two more compounds were corrected with their 232 
own ILIS (carbamazepine 10,11-epoxide and enalaprilat). It is interesting to notice that the ILIS 233 
carbamazepine 10,11-epoxide-d10 did not fully correct matrix effects for its own analyte. Similar 234 
situation has been reported for some labelled compounds with a high degree of deuterated atoms 235 
(Ripollés et al. 2012). It seems that the isotope-labelled compound and the analyte had different 236 
physico-chemical behaviour, leading to an (unexpected) unsatisfactory correction. A possible 237 
explanation could be related to different hydrolysis kinetics between labelled and unlabelled 238 
epoxide metabolites caused by the presence of deuteriums in the hydrolysis site. 239 
Regarding EWW, notably matrix effects are normally expected. In previous works 240 
(Gracia-Lor et al. 2011 and 2012) the use of ILIS was the alternative chosen to compensate for 241 
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matrix effects in pharmaceutical analysis in water. When the analyte ILIS is not available, the 242 
use of an analogue might be satisfactory, although commonly it can not ensure appropriate 243 
correction for all analyte/water sample combinations (Gracia-Lor et al. 2012). In the present 244 
work, the availability of only three ILIS made the correction of matrix effects problematic. 245 
Sample dilution might be a good alternative, also simple and fast, if sufficient sensitivity is 246 
achieved by the analytical method. After testing different dilutions of sample with HPLC-grade 247 
water, a 4-fold dilution was found to be adequate for accurate quantification, also maintaining a 248 
satisfactory sensitivity. Spiking levels tested in the non-diluted effluent wastewaters from 249 
different WWTPs were 0.1 and 0.4 g/L (i.e. 0.025 and 0.1 g/L in the 4-diluted samples). In 250 
general, recoveries and precision were satisfactory for most compounds at both fortification 251 
levels (Table 3). Two metabolites of dipyrone (4-acetamido antipyrine and 4-formyl antipyrine) 252 
could not be validated in some samples due to the high concentrations found in the non-spiked 253 
samples. Low recoveries were obtained for clofibric acid, fenofibric acid and clopidogrel at both 254 
levels due to signal suppression that could not be compensated by sample dilution (x 4). On the 255 
contrary, some analytes (e.g. losartan carboxylic acid, N-acetyl sulfamethoxazole, 5-hydroxy 256 
omeprazole or enalapril) yielded values above 120% in several samples. This behaviour was also 257 
observed in SW, as previously commented. 258 
Enalaprilat could not be validated at the lowest level assayed (0.1 µg/L) due to its low 259 
sensitivity. At the highest concentration (0.4 g/L), the average recovery was 66%, which could 260 
be improved to 108% by correction of matrix effects thanks to the availability of ILIS 261 
enalaprilat-d5. As occurred in SW, the use of ILIS carbamazepine 10,11-epoxide-d10 did not fully 262 
correct matrix effects for its own analyte leading to recoveries of 45% and 74% at the low and 263 
high spiking concentrations, respectively. 264 
It is worth to notice the case of omeprazole, which could not be validated in EWW 265 
probably due to its low stability. In order to evaluate the stability of the omeprazole standard, an 266 
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individual new solution of this pharmaceutical was prepared, and injected in the LC-MS/MS 267 
instrument every 268 
 24 
Table 3. Method validation for effluent  wastewater. Recovery (%) and relative standard deviation (RSD%) for six different EWW samples 269 
spiked at 0.1 and 0.4 g/L. Each sample was analyzed in triplicate. 270 
Compound 
Recovery (%) at 0.1 g/L 
Average 
Recovery (%) at 0.4 g/L 
Average 
Average 
LOQ (ng/L) 
LOQ range 
(ng/L) EWW1 EWW2 EWW3 EWW4 EWW5 EWW6 EWW1 EWW2 EWW3 EWW4 EWW5 EWW6 
Carbamazepine 118 90 112 114 89 113 106 (12) 125 115 87 111 100 110 108 (12) 17.3 7.5 – 31.3 
Carbamazepine  10,11-epoxide 107 119 116 107 107 118 112 (5) 137 137 96 144 137 131 130 (13) 36.1 21.6 – 56.3 
Carbamazepine 10,11-epoxide* 35 57 41 42 41 53 45 (19) 80 78 58 79 79 71 74 (12) 
10,11- Dihydro-10,11-dihydroxy 
carbamazepine 
96 97 111 a 70 88 92 (16) 126 118 91 134 137 142 125 (19) 144.9 71.1 – 287.1 
                 Clarithromycin 121 139 115 119 135 127 126 (8) 104 95 62 98 111 67 90 (22) 13.5 3.5 – 24.7 
N-Desmethyl clarithromycin 97 107 89 102 106 92 99 (8) 74 71 57 72 90 57 70 (17) 13.8 4.6 – 19.4 
Clopidogrel 29 31 32 27 39 41 33 (17) 53 55 53 61 46 53 53 (9) 1.8 0.7 – 2.7 
Clopidogrel carboxylic acid 99 114 136 96 102 119 111 (14) 113 124 111 108 99 91 108 (11) 15.7 10.1 – 21.8 
                 Enalapril 138 153 136 149 141 156 146 (6) 158 149 146 163 107 171 149 (15) 132.7 85.0 -179.7 
Enalaprilat b b b b b b b 89 68 70 70 59 42 66 (23) 513 348 - 693 
Enalaprilat* b b b b b b b 105 117 80 106 106 132 108 (16) 
                 Losartan 96 109 92 96 111 124 105 (12) 116 111 68 109 103 103 102 (17) 5.9 3.2 – 13.0 
Losartan carboxylic acid 131 153 182 183 149 207 168 (17) 197 166 113 165 159 132 155 (19) 44.5 25.2 – 77.5 
                 Omeprazole c c c c c c c c c c c c c c 
- - 
Omeprazole* c c c c c c c c c c c c c c 
4-Hydroxy omeprazole sulfide 94 123 91 107 114 81 102 (16) 104 120 94 105 121 97 107 (11) 37.2 19.6 – 60.1 
5-Hydroxy omeprazole 103 132 145 132 108 117 123 (13) 137 139 124 137 129 123 131 (5) 33.9 9.5 – 60.1 
                 Sulfamethoxazole 71 59 134 100 108 115 98 (29) 92 110 74 97 103 100 96 (13) 64.3 35.1 – 77.9 
N-Acetyl sulfamethoxazole 73 143 112 112 154 140 123 (24) 112 129 119 115 128 118 120 (6) 56.9 32.4 – 80.8 
                 4-Acetamidoantipyrine a a a a a 83 83 a a a a a 106 106 60.3 60.3 
4-Aminoantipyrine 55 64 64 49 a a 58 (13) 47 48 88 59 a 59 60 (28) 130.8 54.8 – 310.1 
4-Formylaminoantipyrine 149 a a 118 a a 134 (16) 216 222 a 109 179 a 182 (29) 129.5 84.9 –189.3 
                 Clofibric acid 51 51 30 51 46 40 45 (19) 51 52 41 29 29 26 38 (30) 106.8 78.7 – 160.0 
                 Fenofibric acid 47 65 41 58 65 67 57 (19) 65 65 52 44 59 59 58 (14) 5.9 4.7 – 8.5 
 271 
a: Not estimated due to the high analyte levels found in the “blank” sample.; b: Not estimated due to the poor sensitivity; c: Not estimated due to the standard 272 
degradation. 273 
* Recoveries calculated using their own ILIS 274 
In bold the parent pharmaceuticals and with regular format, the metabolites. 275 
 25 
individual new solution of this pharmaceutical was prepared, and injected in the LC-MS/MS 276 
instrument every week. As can be seen in Figure 3a, the omeprazole signal notably decreased 277 
along the time, while in parallel the concentration of 4-hydroxy omeprazole sulfide, which was 278 
not included in the standard solution, increased (Figure 3b). Thus, it seems clear that 279 
omeprazole was unstable in aqueous solution and was transformed to 4-hydroxy omeprazole 280 
sulfide. The degradation of omeprazole to the sulfide derivative in HPLC-grade water and kept 281 
in dark has been previously reported in literature (DellaGreca et al. 2006). In our study, the 282 
transformation started to be more evident after 14 days of storage in the cooler (-4 ºC, 283 
darkness). Thus, to avoid a wrong quantification for omeprazole and 4-hydroxy omeprazole 284 
sulfide when analyzing real samples, standards should be renewed weekly. 285 
LOQs were estimated for every water sample tested (i.e., 6 SW and 6 EWW). For SW, 286 
average LOQs ranged from 0.4 to 7.7 ng/L (Table 2). The two exceptions were clofibric acid 287 
and enalapril, which presented low sensitivity, with the result of higher LOQs (around 25 ng/L 288 
in SW). With the exception of enalaprilat, average LOQs for EWW varied from 1.8 to 145 289 
ng/L: for 3 compounds LOQs were < 6 ng/L, and for another 10 analytes they were lower than 290 
60 ng/L (Table 3). As can be seen, in several cases the LOQs varied notably from one sample 291 
to other. This highlights once more that matrix effects can be rather different from one sample 292 
to another. Therefore, giving an LOQ value estimated just from a given sample, as reported in 293 
most of papers, might not be realistic. Consequently, LOQ reported should be taken with 294 
precaution, as the situation may be rather different when applying the method to a set of real-295 
world samples. Concerning IDLs, they ranged from 0.3 to 10 pg, except for clofibric acid, the 296 
only compound that was measured in negative ionization mode (Table 1).   297 
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Figure 3 LC-MS/MS chromatograms for (a) omeprazole reference standard (100 g/L) injected in different days after preparation of the 300 
standard solution (b) 4-hydroxy omeprazole sulfide formed by degradation of omeprazole. 301 
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 302 
3.5 Application to water samples 303 
The developed methodology was applied to the analysis of 12 SW samples collected at 304 
selected sites from the Spanish Mediterranean area of Valencia and 12 EWW samples from 305 
different WWTPs of this area.  306 
In every sequence of sample analysis, the calibration curve was injected twice, at the 307 
beginning and the end of the sample batch. Moreover, quality control samples (QCs) were 308 
included in every sample sequence. QCs consisted on SW or EWW samples spiked at the LOQ 309 
level. They were prepared randomly selecting one of the water samples analyzed within the 310 
batch, following the same analytical procedure than for the samples. In the case that the sample 311 
used for QC preparation contained any of the compounds analyzed, the concentration 312 
calculated in the sample was subtracted from that calculated in the spiked sample. 313 
Confirmation of positive findings was carried out by calculating the peak area ratios 314 
between the quantification (Q) and confirmation (q1 and q2) transitions. As three transitions 315 
were acquired, two intensity ion-ratios could be used for confirmation of the identity. The 316 
finding was considered as positive when the experimental ion-ratios were within the tolerance 317 
range (European Union Decision 2002/657/EC) and the retention time of the compound in the 318 
sample within ±2.5% the retention time of the reference standard. 319 
All parent compounds, except omeprazole, were detected in the surface water samples 320 
at least once (Table 4). Regarding metabolites, only three of them (4-amino antipyrine, 321 
clofibric acid and enalapilat) were never found. The highest concentrations corresponded to the 322 
dipyrone metabolites 4-acetamido antipyrine and 4-formylamino antipyrine (0.89 and 0.87 323 
µg/L, respectively). Dipyrone is a pro-drug widely used as antipyretic. Its main metabolites 324 
have been previously studied in several works, and high concentrations have been reported 325 
(Martínez Bueno et al. 2007; Rosal et al. 2010).   326 
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Table 4. Summary of the compounds detected in the analysis of surface and effluent wastewater samples 327 
 328 
Compounds 
SW (n = 12) EWW (n = 12) 
Min 
Level 
(g/L) 
Max 
Level 
(g/L) 
Median 
(g/L) 
% 
positive 
findings 
Min 
Level 
(g/L) 
Max 
Level 
(g/L) 
Median 
(g/L) 
% 
positive 
findings 
Carbamazepine 0.002 0.026 0.009 58 0.43 2.76 1.01 100 
Carbamazepine 10,11-epoxide  < LOQ < LOQ < LOQ 17 n.d. n.d. n.d. 0 
10,11- Dihydro-10,11-dihydroxy 
carbamazepine 
0.004 0.374 0.048 92 0.55 6.85 1.76 100 
 Clarithromycin < LOQ 0.012 0.004 67 0.04 0.39 0.09 67 
N-Desmethyl clarithromycin < LOQ 0.004 0.004 50 0.04 0.15 0.09 100 
 Clopidogrel < LOQ 0.002 0.002 100 0.006 0.022 0.008 100 
Clopidogrel carboxylic acid 0.002 0.012 0.003 67 0.09 0.61 0.20 100 
 Enalapril < LOQ < LOQ < LOQ 8 n.d. n.d. n.d. 0 
Enalaprilat n.d. n.d. n.d. 0 n.d. n.d. n.d. 0 
 Losartan 0.003 0.099 0.004 67 0.03 0.37 0.29 100 
Losartan carboxylic acid <LOQ 0.116 0.009 67 0.01 1.56 0.49 100 
 Omeprazole n.d. n.d. n.d. 0 n.d. n.d. n.d. 0 
4-Hydroxy omeprazole sulphide <LOQ 0.028 < LOQ 33 0.06 0.29 0.11 100 
5-Hydroxy omeprazole 0.004 0.004 0.004 8 0.12 0.25 0.22 58 
 Sulfamethoxazole < LOQ < LOQ < LOQ 8 0.05 1.86 0.11 100 
N-Acetyl sulfamethoxazole < LOQ < LOQ < LOQ 33 0.03 0.96 0.09 100 
 4-Acetamido antipyrine 0.002 0.894 0.068 75 0.49 7.91 3.20 100 
4-Amino antipyrine n.d. n.d. n.d. 0 0.53 7.98 0.85 25 
4-Formylamino antipyrine 0.037 0.871 0.079 67 0.98 5.76 3.23 100 
 Clofibric acid n.d. nd n.d. 0 n.d. n.d. n.d. 0 
 Fenofibric acid 0.008 0.182 0.020 33 0.01 0.36 0.23 100 
n.d.: Not detected, i.e., none transition was observed 329 
<LOQ: Both quantification and confirmation transitions were observed but the concentration level was lower than the LOQ shown in Tables 2-3)  330 
 331 
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Median concentrations for most of the compounds were lower than 0.01 µg/L. The 332 
metabolite 10,11-dihydro-10,11-dihydroxy carbamazepine was however present at  higher 333 
concentrations. This compound was found in 92% of the samples in contrast to the other 334 
carbamazepine metabolite studied in this work (carbamazepine 10,11-epoxide), which was only 335 
present in 17% of the samples. This is in accordance with the metabolism of carbamazepine. 336 
This pharmaceutical, used for the treatment of epilepsy, schizophrenia and bipolar disorder, 337 
undergoes extensive metabolism by cytochrome P450 system in the liver. Carbamazepine seems 338 
not to be efficiently removed in WWTPs, which may explain its frequent detection in 339 
environmental samples (Radjenovic et al. 2009; Langford and Thomas 2011). Also in agreement 340 
with our findings is the fact that the most relevant metabolite 10,11-dihydro-10,11-dihydroxy 341 
carbamazepine was widely detected in waters, and to a lesser extent the metabolite 342 
carbamazepine 10,11-epoxide (Miao and Metcalfe 2003). It is worth to notice that most of 343 
papers dealing with the presence of carbamazepine and metabolites in the aquatic environment 344 
only take into account carbamazepine 10,11-epoxide (Langford and Thomas 2011; Valcárcel et 345 
al. 2011; López-Serna et al. 2012a; Jelic et al. 2012), despite that higher concentrations are 346 
commonly found for 10,11-dihydro-10,11-dihydroxy carbamazepine (Miao and Metcalfe 2003). 347 
This might be due to the fact that the epoxide is the active metabolite of carbamazepine (Miao 348 
and Metcalfe 2003).  349 
In relation to effluent wastewater samples, 13 out of 21 compounds were detected in 350 
100% of the samples, which illustrates the ubiquity of these compounds in the wastewaters. All 351 
parent compounds, except omeprazole and enalapril, were frequently detected. In the case of 352 
omeprazole, despite being one of the most consumed pharmaceuticals in Spain, it was not 353 
detected in any of the samples. On the contrary, the two omeprazole metabolites included in this 354 
study were detected, and one of them (4-hydroxy omeprazole sulfide) was found in all the 355 
samples analyzed (Table 4).  This is in agreement with our previous research on omeprazole 356 
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metabolism and on its transformation products in water Boix et al. 2013a and 2013b. Enalapril 357 
and enalaprilat (its active metabolite) were not detected in any of the water samples. Both 358 
compounds are frequently found in influent wastewater (Gracia-Lor et al. 2010; Tarcomnicu et 359 
al. 2011) but they are much less ubiquitous in EWW.  360 
Sulfamethoxazole and its N-acetyl derivate were found in all EWW samples at similar 361 
average concentration level. Despite the derivative does not have pharmacological activity, it 362 
however presents ecotoxicity (López-Serna et al. 2012a).  363 
The highest concentrations were by far for dipyrone metabolites, with maximum 364 
concentrations around 8 µg/L, for both 4-acetamido antipyrine and 4-amino antipyrine, while 4-365 
formylamino antipyrine reached a maximum value around 6 µg/L. 4-amino antipyrine was was 366 
present in 25% of the samples while the other two were found in all the effluent wastewaters 367 
analyzed.  368 
Similarly, the concentrations of the pharmaceuticals losartan, carbamazepine and 369 
especially for clopidogrel were lower than for their metabolites. As occurred in surface waters, 370 
high levels of 10,11-dihydro-10,11-dihydroxy carbamazepine were found due to the extensive 371 
metabolism of carbamazepine.  372 
Regarding the pro-drugs, only fenofibric acid was detected while clofibric acid was not 373 
found in any sample. The latter might be explained by a lower consumption of this 374 
pharmaceutical this area (it is not within the list of the most consumed pharmaceuticals in Spain) 375 
and/or to some kind of transformation/degradation in the sewer system or in the aquatic 376 
environment, all these facts making making its detection in water samples unlikely. 377 
Illustrative UHPLC-MS/MS chromatograms are shown in Figure 4 for a EWW sample 378 
that was positive for up to 16 compounds, with concentrations varying from 0.02 g/L 379 
(clopidogrel) to 7.98 g/L (4-amino antipyrine).  380 
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Figure 4 382 
LC–MS/MS chromatograms (Q transition) for an effluent wastewater that was positive to 16 compounds (5 pharmaceuticals and 11 metabolites). 383 
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4. CONCLUSIONS 
The analytical method developed in this work, based on the use of UHPLC-MS/MS with 
triple quadrupole analyzer, has allowed the simultaneous determination of 21 analytes, 
including seven parent pharmaceuticals and 14 major metabolites, in surface water and urban 
effluent wastewater samples. In order to have a more realistic overview on the method 
performance and its applicability to different water samples, the method was validated in 
twelve different matrices (six surface water and six effluent wastewater samples) at several 
concentration levels. In absence of most of analyte ILIS, a 4-dilution of the effluent 
wastewater samples was found a rapid, simple and rather efficient approach to minimize 
signal suppression or enhancement due to matrix effects in this complex matrix. Confirmation 
of the analyte identity was guaranteed by acquiring 3 SRM transitions and evaluating their 
Q/q ratios and retention time.  
The application of this method to water samples showed that 6 out of 14 metabolites were 
present in 50% of the surface samples analyzed. Regarding effluent wastewater, 9 out of 14 
metabolites were detected in 100% of the samples. Interestingly, metabolite concentrations 
were on the same order or even higher than those of the parent compound. This illustrates the 
importance of including metabolites and transformation products in the methods applied for 
water analysis in order to have a wider and realistic knowledge on the occurrence and fate of 
pharmaceuticals in the aquatic environment.  
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FIGURE CAPTIONS  
Figure 1. Structures of the selected compounds. 
Figure 2. Recoveries obtained for 19 selected compounds after SPE with Oasis HLB (60 mg) 
at different sample pH values. Clopidogrel and losartan recoveries are not shown because their 
standards were not available at the laboratory when this test was carried out. 
Figure 3. LC-MS/MS chromatograms for (a) omeprazole reference standard (100 g/L) 
injected in different days after preparation of the standard solution (b) 4-hydroxy omeprazole 
sulfide formed by degradation of omeprazole. 
Figure 4. LC–MS/MS chromatograms (Q transition) for an effluent wastewater that was 
positive to 16 compounds (5 pharmaceuticals and 11 metabolites). 
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